These findings align closely with previous human studies involving carcinoma of breast cancer [19], ovarian cancer [20], lymphocytic leukemia [21,22], and lymphoma [23], suggesting that PGRN levels may be elevated in various types of tumors, rather than being specific to individual tumor types. This evidence concerns the gene GRN and ovarian carcinoma.